Monoamine Reuptake Inhibitor Research
A triple monoamine reuptake inhibitor (DAT, NET, SERT) originally developed by NeuroSearch as a candidate for neurodegenerative disease research. Studied in published clinical and preclinical literature for its effects on energy balance and hypothalamic monoamine signaling pathways.
Published clinical and preclinical studies have administered tesofensine orally at microgram-to-milligram daily doses, with endpoints measured in body composition, resting energy expenditure, and serum monoamine metabolites. The long elimination half-life supports once-daily dosing schedules in published research.
The obesity and energy-balance research community has focused on tesofensine because its triple-uptake-inhibitor profile (DAT/NET/SERT) produces a different pharmacological signature than single-target appetite suppressants — providing a probe for studying combined monoaminergic effects on satiety, metabolic rate, and central reward circuits. Originally developed for neurodegenerative disease research, the energy-balance effects emerged as an unexpected finding in those trials.
For research purposes only. Not intended for consumption, clinical application, or diagnostic use.